高级检索
国际生物制品学杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
尿酸氧化酶临床疗效和安全性评价
黄琳秋
江筠
楼觉人 [综述]
作者及单位信息
·
DOI： 10.3760/cma.j.issn.1673-4211.2016.02.009
Clinical efficacy and safety evaluation of urate oxidase
Huang Linqiu
Jiang Yun
Lou Jueren
Authors Info & Affiliations
Huang Linqiu
No.2 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200052, China
Jiang Yun
Lou Jueren
·
DOI： 10.3760/cma.j.issn.1673-4211.2016.02.009
2720
33
0
0
2
1
PDF下载
APP内阅读
摘要

血尿酸水平升高会引起高尿酸血症，尿酸氧化酶能将尿酸分解进而降低血尿酸水平。近年来，随着生物技术的发展，尿酸氧化酶作为分解尿酸的生物制剂已被批准上市，但其有效性和安全性还有待进一步研究和评估。此文对近年用于治疗高尿酸血症的上市尿酸酶类药品及其临床应用疗效和安全性进行综述，并对尿酸氧化酶应用存在的问题和今后的研究方向做了展望。

尿酸氧化酶;高尿酸血症;治疗结果;安全性
ABSTRACT

Hyperuricemia is a condition of abnormally high uric acid level in blood. Urate oxidase catalyzes enzymatic oxidation of uric acid to provide sustained reduction of plasma uric acid level. With the development of biotechnology, urate oxidase has been approved as a urate-lowering biological agent. Its efficacy and safety need further research and evaluation. This review summarizes the clinical application and efficacy and safety of urate oxidase as urate-lowering agent for hyperuricemia in recent years. The problems of application and future research directions are also discussed.

Urate oxidase;Hyperuricemia;Treatment outcome;Safety
Lou Jueren, Email: mocdef.oabib-elihnereujuol
Shanghai Science and Technology Infrastructure Program (15431906200)
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

黄琳秋,江筠,楼觉人. 尿酸氧化酶临床疗效和安全性评价[J]. 国际生物制品学杂志,2016,39(2)：92-96.

DOI:10.3760/cma.j.issn.1673-4211.2016.02.009

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

尿酸氧化酶(urate oxidase)也称尿酸酶，是生物体内嘌呤降解代谢途径中的一种氧化酶。它能以氧作为受体，专一性催化尿酸氧化生成尿囊素、二氧化碳和过氧化氢。尿酸酶广泛存在于自然界的多个物种体内，但人的尿酸酶基因编码33和187位精氨酸密码子无义突变成终止密码子，故人体不能合成有活性的尿酸酶 [ 1 ]。因此，当人体血液中尿酸水平超过尿酸血浆饱和浓度70 mg/L时，会形成高尿酸血症，长期累积则导致痛风综合征、肾结石乃至肾功能不全 [ 2 ]。从20世纪50年代开始，尿酸酶已成为研究热点，且外源性尿酸酶已作为生物制剂获准用于临床。用作治疗的尿酸酶能很快降低血尿酸浓度，并催化肾脏和关节中的尿酸沉淀快速分解为尿囊素，尿囊素的溶解度是尿酸的5～10倍，易于通过肾脏排出体外，从而达到降低尿酸的目的。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Wu XW , Lee CC , Muzny DM ,et al. Urate oxidase: primary structure and evolutionary implications[J]. Proc Natl Acad Sci U S A, 1989,86(23)：9412-9416. DOI: 10.1073/pnas.86.23.9412 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Grobner W , Zollner N . Uricosuric therapy and urate solubility in blood and urine[J]. Postgrad Med J, 1979,55Suppl 3：26-31.
返回引文位置Google Scholar
百度学术
万方数据
[3]
Luo X , Cai N , Cheng Z . Determination of uric acid in plasma by LC-MS/MS and its application to an efficacy evaluation of recombinant urate oxidase[J]. Anal Sci, 2013,29(7)：709-713. DOI: 10.2116/analsci.29.709 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Colloc'h N , Girard E , Dhaussy AC ,et al. High pressure macromolecular crystallography: the 140-MPa crystal structure at 2.3 Å resolution of urate oxidase, a 135-kDa tetrameric assembly[J]. Biochim Biophys Acta, 2006,1764(3)：391-397. DOI: 10.1016/j.bbapap.2006.01.006 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Kratzer JT , Lanaspa MA , Murphy MN ,et al. Evolutionary history and metabolic insights of ancient mammalian uricases[J]. Proc Natl Acad Sci U S A, 2014,111(10)：3763-3768. DOI: 10.1073/pnas.1320393111 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Pui CH , Evans WE , Mahmoud HH ,et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies[J]. Leukemia, 1997,11(11)：1813-1816. DOI: 10.1038/sj.leu.2400850 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Cheuk DK , Chiang AK , Chan GC ,et al. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer[J]. Cochrane Database Syst Rev, 2014,8：D6945. DOI: 10.1002/14651858.CD006945.pub3 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Patte C , Sakiroglu O , Sommelet D . European experience in the treatment of hyperuricemia[J]. Semin Hematol, 2001,38(4Suppl 10)：9-12. DOI: 10.1016/S0037-1963(01)90038-1 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Leach M , Parsons RM , Reilly JT ,et al. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy[J]. Clin Lab Haematol, 1998,20(3)：169-172. DOI: 10.1046/j.1365-2257.1998.00124.x .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Pui CH . Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience[J]. Semin Hematol, 2001,38(4Suppl 10)：13-21. DOI: 10.1016/S0037-1963(01)90039-3 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Yim BT , Sims-McCallum RP , Chong PH . Rasburicase for the treatment and prevention of hyperuricemia[J]. Ann Pharmacother, 2003,37(7/8)：1047-1054. DOI: 10.1345/aph.1C336 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Kennedy LD , Ajiboye VO . Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome[J]. J Oncol Pharm Pract, 2010,16(3)：205-213. DOI: 10.1177/1078155209348719 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Pui CH , Mahmoud HH , Wiley JM ,et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma[J]. J Clin Oncol, 2001,19(3)：697-704.
返回引文位置Google Scholar
百度学术
万方数据
[14]
Abdellatif AA , Elkhalili N . Management of gouty arthritis in patients with chronic kidney disease[J]. Am J Ther, 2014,21(6)：523-534. DOI: 10.1097/MJT.0b013e318250f83d .
返回引文位置Google Scholar
百度学术
万方数据
[15]
de Bont JM , Pieters R . Management of hyperuricemia with rasburicase review[J]. Nucleosides Nucleotides Nucleic Acids, 2004,23(8/9)：1431-1440. DOI: 10.1081/NCN-200027656 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Allen KC , Champlain AH , Cotliar JA ,et al. Risk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) project[J]. Drug Saf, 2015,38(2)：183-187. DOI: 10.1007/s40264-014-0255-7 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Goth L , Nagy T . Inherited catalase deficiency: is it benign or a factor in various age related disorders[J]. Mutat Res, 2013,753(2)：147-154. DOI: 10.1016/j.mrrev.2013.08.002 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Roberts DA , Freed JA . Rasburicase-induced methemoglo-binemia in two African-American female patients: an under-recognized and continued problem[J]. Eur J Haematol, 2015,94(1)：83-85. DOI: 10.1111/ejh.12350 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Brant JM . Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome[J]. Clin J Oncol Nurs, 2002,6(1)：12-16. DOI: 10.1188/02.CJON.12-16 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Shannon JA , Cole SW . Pegloticase: a novel agent for treatment-refractory gout[J]. Ann Pharmacother, 2012,46(3)：368-376. DOI: 10.1345/aph.1Q593 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
White S , Mounsey A , Tillett J . Clinical inquiry: which prophylactic therapies best prevent gout attacks[J]. J Fam Pract, 2014,63(4)：216, 221.
返回引文位置Google Scholar
百度学术
万方数据
[22]
Hershfield MS , Ganson NJ , Kelly SJ ,et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients[J]. Arthritis Res Ther, 2014,16(2)：R63. DOI: 10.1186/ar4500 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Yue CS , Huang W , Alton M ,et al. Population pharmaco-kinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout[J]. J Clin Pharmacol, 2008,48(6)：708-718. DOI: 10.1177/0091270008317589 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Sundy JS , Becker MA , Baraf HS ,et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase Ⅱ randomized study[J]. Arthritis Rheum, 2008,58(9)：2882-2891. DOI: 10.1002/art.23810 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Kydd AS , Seth R , Buchbinder R ,et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews[J]. J Rheumatol Suppl, 2014,92：33-41. DOI: 10.3899/jrheum.140460 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Lee CC , Wu XW , Gibbs RA ,et al. Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase[J]. Science, 1988,239(4845)：1288-1291. DOI: 10.1126/science.3344434 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Zhang C , Fan K , Luo H ,et al. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant[J]. Int J Pharm, 2012,430(1/2)：307-317. DOI: 10.1016/j.ijpharm.2012.03.057 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Baldo BA . Enzymes approved for human therapy: indications, mechanisms and adverse effects[J]. BioDrugs, 2015,29(1)：31-55. DOI: 10.1007/s40259-015-0116-7 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Sriranganathan MK , Vinik O , Bombardier C ,et al. Interventions for tophi in gout[J]. Cochrane Database Syst Rev, 2014,10：D10069. DOI: 10.1002/14651858.CD010069.pub2 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Holdsworth MT , Nguyen P . Role of i．v. allopurinol and rasburicase in tumor lysis syndrome[J]. Am J Health Syst Pharm, 2003,60(21)：2213-2222.
返回引文位置Google Scholar
百度学术
万方数据
[31]
Yang X , Yuan Y , Zhan CG ,et al. Uricases as therapeutic agents to treat refractory gout: current states and future directions[J]. Drug Dev Res, 2012,73(2)：66-72. DOI: 10.1002/ddr.20493 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Richette P , Garay R . Novel drug discovery strategies for gout[J]. Expert Opin Drug Discov, 2013,8(2)：183-189. DOI: 10.1517/17460441.2013.742061 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
楼觉人，Email: mocdef.oabib-elihnereujuol
B
上海市科技支撑计划 (15431906200)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
达雷妥尤单抗治疗晚期轻链型淀粉样变的疗效和安全性
沈恺妮 等
中华血液学杂志 2022,43(01)
奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析
张宇 等
中华皮肤科杂志 2021,54(07)
痛风及高尿酸血症基层诊疗指南（2019年）
中华医学会 等
中华全科医师杂志 2020,19(04)
中国高尿酸血症与痛风诊疗指南(2019)
中华医学会内分泌学分会
中华内分泌代谢杂志 2020,36(01)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大